Clinical Trial Update: Subretinal Macugen® for Neovascular Age-Related Macular Degeneration [Phase 3]

View source ↗

Summary

Update on a Phase 3 trial of Macugen (pegaptanib) delivered subretinally for neovascular age-related macular degeneration; the current status of the trial is un…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Macugen (pegaptanib sodium)

Snippet

Sponsor: Klinikum Ludwigshafen | Conditions: Age-related Macular Degeneration | Phase 3 | Status: UNKNOWN